Literature DB >> 18781259

Ocular mucous membrane pemphigoid: diagnosis and management strategies.

Valerie P J Saw1, John K G Dart.   

Abstract

Ocular mucous membrane pemphigoid presents some of the most challenging dilemmas in anterior segment management. Diagnosis is made difficult by the insensitivity of immunopathological investigations and the differential diagnosis of other scarring conjunctival disorders. The management of the associated ocular surface disease involves control of blepharitis, dry eye, filamentary keratitis, keratinization, lid malposition, and persistent epithelial defect, as well as the identification and avoidance of toxicity. Inflammation associated with the underlying disorder demands the use of systemic immunosuppressive therapy in many patients. New biological immunotherapies have been used when conventional immunosuppressive therapies fail. Ophthalmic plastic surgery is essential for the management of lid malposition and corneal exposure. Improving vision may require the use of specialized contact lenses, cataract surgery, and corneal and ocular surface reconstructive surgery. All surgery must be integrated with ocular surface treatment and immunosuppressive treatment to avoid disease exacerbations.

Entities:  

Mesh:

Year:  2008        PMID: 18781259     DOI: 10.1016/s1542-0124(12)70281-1

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  17 in total

1.  Turning a blind eye: ocular mucous membrane pemphigoid.

Authors:  Suran Loshana Fernando; Phillip Myers
Journal:  BMJ Case Rep       Date:  2009-07-26

Review 2.  Ocular mucous membrane pemphigoid: a review.

Authors:  Samanta Taurone; Marialuisa Spoletini; Massimo Ralli; Pietro Gobbi; Marco Artico; Laszlò Imre; Cecília Czakò; Illés Kovàcs; Antonio Greco; Alessandra Micera
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

3.  Incidence, clinical features and diagnosis of cicatrising conjunctivitis in Australia and New Zealand.

Authors:  Samantha Bobba; Connor Devlin; Nick Di Girolamo; Denis Wakefield; Peter McCluskey; Elsie Chan; Mark Daniell; Stephanie Watson
Journal:  Eye (Lond)       Date:  2018-06-19       Impact factor: 3.775

Review 4.  The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

Authors:  J K Dart
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

5.  Short-term High Fructose Intake Reprograms the Transcriptional Clock Rhythm of the Murine Extraorbital Lacrimal Gland.

Authors:  Dingli Lu; Cuipei Lin; Xinwei Jiao; Zongming Song; Liya Wang; Jianqin Gu; Zhijie Li
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-05-01       Impact factor: 4.799

6.  Aldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring.

Authors:  Sarah D Ahadome; David J Abraham; Suryanarayana Rayapureddi; Valerie P Saw; Daniel R Saban; Virginia L Calder; Jill T Norman; Markella Ponticos; Julie T Daniels; John K Dart
Journal:  JCI Insight       Date:  2016-08-04

Review 7.  Linking immune responses with fibrosis in allergic eye disease.

Authors:  Sarah B Dale; Daniel R Saban
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-10

8.  Elevation of conjunctival epithelial CD45INTCD11b⁺CD16⁺CD14⁻ neutrophils in ocular Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Geraint P Williams; Paul J Tomlins; Alastair K Denniston; H Susan Southworth; Sreekanth Sreekantham; S John Curnow; Saaeha Rauz
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-07-10       Impact factor: 4.799

Review 9.  [Mucous membrane pemphigoid].

Authors:  M M Holtsche; D Zillikens; E Schmidt
Journal:  Hautarzt       Date:  2018-01       Impact factor: 0.751

10.  Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom.

Authors:  G P Williams; C Radford; P Nightingale; J K G Dart; S Rauz
Journal:  Eye (Lond)       Date:  2011-07-29       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.